Drug Discovery Chemistry Platform Unit

Unit Leader

Hiroo Koyama

Ph.D.

Hiroo Koyama

Show

Hide

1987
Ph.D., Graduate School of Pharmaceutical Sciences, The University of Tokyo
1987
Postdoctoral Fellow, Department of Chemistry, Massachusetts Institute of Technology, USA
1990
New Lead Research Laboratories, Sankyo, Co. Ltd.
1991
Senior Research Fellow, Department of Medicinal Chemistry, Merck Research Laboratories, USA
2010
Principal Scientist, Chemistry, PTC Therapeutics Inc., USA
2013
Senior Research Scientist, Drug Discovery Chemistry Platform Unit, RIKEN Center for Molecular Imaging Science
2013
Platform Unit Leader, Drug Discovery Chemistry Platform Unit, RIKEN Center for Life Science Technologies
2018
Unit Leader, Drug Discovery Chemistry Platform Unit, RIKEN Center for Sustainable Resource Science (-current)

Contact

hiroo.koyama

Drug Discovery Chemistry Platform Unit,
Drug Discovery Platforms Cooperation Division,
RIKEN Center for Sustainable Resource Science

#628 6F Main Research Building,
2-1 Hirosawa, Wako, Saitama 351-0198 Japan
Access to Wako

Related links

Outline

Drug Discovery Chemistry Platform Unit
As a part of the drug discovery efforts at RIKEN, our group’s research is focused on 1) small molecule drug discovery, 2) targeted protein degradation, and 3) chemistry-related general support for the drug discovery efforts of our collaborators at various academic and governmental research institutions in Japan.  We specialize on programs with novel therapeutic targets or mode of action, and strive to quickly develop structure-activity relationships on HTS hits in a wide range of therapeutic areas including rare diseases, neglected tropical diseases, and intractable cancers. While identification of a preclinical candidate is the ideal outcome, validation of novel therapeutic targets is also an important part of our efforts.

Subjects

  1. Small molecule drug discovery and targeted protein degradation
Area of research in small molecule drug discovery